Vanguard Capital Management’s Prime Medicine PRME Stock Holding History
Bought
Maintained
Sold
Other funds holding PRME
Vanguard Capital Management's PRME Position: Q3 2026 in Review
Vanguard Capital Management increased its Prime Medicine (PRME) stake by 1.3% in Q3 2026, buying an estimated $189K and bringing the position to 4,579,587 shares worth $14M. The position accounts for ﹤0.01% of the portfolio, ranked #2582.
Vanguard Capital Management first reported a position in PRME in Q1 2026 and has held it in 3 quarters since. The position peaked at $16.7M in Q2 2026. 185 funds tracked by Wall St. Rank hold PRME as of Q3 2026.
- Vanguard Capital Management held 4,579,587 shares of Prime Medicine worth $14M as of Q3 2026.
- Vanguard Capital Management bought 56,947 Prime Medicine shares in Q3 2026, an estimated $189K.
- Prime Medicine made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2582 holding.
- Vanguard Capital Management first reported a position in Prime Medicine in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Prime Medicine position peaked at $16.7M in Q2 2026.
- 185 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.